These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 4012673)

  • 1. The fibrinolytic action of flufenamate and its influence on plasminogen binding to fibrin.
    Chevallet-Prandini MH; Chapel A; Suscillon M
    Thromb Res; 1985 Jun; 38(5):481-9. PubMed ID: 4012673
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fibrinolytic action of a new semi-synthetic polysaccharide sulfate, galactan polysulfate (DH 6322), in the rat.
    Kumada T; Abiko Y
    Thromb Res; 1985 Jul; 39(1):9-19. PubMed ID: 4035651
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inactivation of purified human alpha 2-antiplasmin and purified human C1 inhibitor by synthetic fibrinolytic agents.
    Miles LA; Burnier JP; Verlander MS; Goodman M; Kleiss AJ; Griffin JH
    Blood; 1981 Jun; 57(6):1015-24. PubMed ID: 6452920
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cleavage of surfactant-incorporating fibrin by different fibrinolytic agents. Kinetics of lysis and rescue of surface activity.
    Günther A; Markart P; Kalinowski M; Ruppert C; Grimminger F; Seeger W
    Am J Respir Cell Mol Biol; 1999 Dec; 21(6):738-45. PubMed ID: 10572071
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [The effect of kringles K1-3, K4 and K5 on lysis of fibrin clots caused by the activation of Glu- and Lys-plasminogen by a tissue activator].
    Taran LD; Makogonenko EM
    Ukr Biokhim Zh (1978); 1989; 61(4):31-6. PubMed ID: 2511651
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adsorption to fibrin of native fragments of known primary structure from human plasminogen.
    Thorsen S; Clemmensen I; Sottrup-Jensen L; Magnusson S
    Biochim Biophys Acta; 1981 May; 668(3):377-87. PubMed ID: 7236714
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of chemical anti-inhibitors on fibrinolytic enzymes and inhibitors.
    Sidelmann J; Jespersen J; Kluft C; Gram J
    Clin Chim Acta; 1997 May; 261(1):43-56. PubMed ID: 9187504
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lys-plasminogen is a significant intermediate in the activation of Glu-plasminogen during fibrinolysis in vitro.
    Fredenburgh JC; Nesheim ME
    J Biol Chem; 1992 Dec; 267(36):26150-6. PubMed ID: 1464625
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Heparin effect on hydrolysis of fibrin clots in a bull and a man with varying fibrinolytic systems].
    Makogonenko EM
    Ukr Biokhim Zh (1978); 1997; 69(5-6):109-16. PubMed ID: 9606832
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Elimination of inhibition in euglobulin fibrinolysis by use of flufenamate: involvement of C1-inactivator.
    Kluft C
    Haemostasis; 1977; 6(6):351-69. PubMed ID: 611048
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterization of a recombinant chimeric plasminogen activator with enhanced fibrin binding.
    Jiao J; Yu M; Ru B
    Biochim Biophys Acta; 2001 Apr; 1546(2):399-405. PubMed ID: 11295444
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Stachybotrydial selectively enhances fibrin binding and activation of Glu-plasminogen.
    Sasaoka M; Wada Y; Hasumi K
    J Antibiot (Tokyo); 2007 Nov; 60(11):674-81. PubMed ID: 18057696
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Features of the interaction of Glu- and Lys-forms of plasminogen with native and partially hydrolyzed fibrin].
    Grinenko TV; Skomorovskaia EV; Kudinov SA; Zolotareva EN
    Biokhimiia; 1992 May; 57(5):728-37. PubMed ID: 1322196
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Direct microscopic monitoring of initial and dynamic clot lysis using plasmin or rt-PA in an in vitro flow system.
    Bizjak N; Bajd F; Vidmar J; Blinc A; Perme MP; Marder VJ; Novokhatny V; Serša I
    Thromb Res; 2014 May; 133(5):908-13. PubMed ID: 24613694
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impaired clot lysis by rt-PA catalyzed mini-plasminogen activation.
    Duboscq C; Genoud V; Parborell MF; Kordich LC
    Thromb Res; 1997 Jun; 86(6):505-13. PubMed ID: 9219330
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fibrin binding. An essential property of anisoylated plasminogen streptokinase activator complex.
    Banton CJ; Overell BG
    Drugs; 1987; 33 Suppl 3():93-6. PubMed ID: 2824169
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differences in the activation rates of plasminogen by tissue plasminogen activator and urokinase.
    Takada A; Shizume K; Cho M; Takada Y
    Thromb Res; 1987 Feb; 45(4):371-81. PubMed ID: 2437668
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Secondary-site binding of Glu-plasmin, Lys-plasmin and miniplasmin to fibrin.
    Suenson E; Thorsen S
    Biochem J; 1981 Sep; 197(3):619-28. PubMed ID: 6459779
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recombinant human C1-inhibitor prevents non-specific proteolysis by mutant pro-urokinase during optimal fibrinolysis.
    Gurewich V; Pannell R
    Thromb Haemost; 2009 Aug; 102(2):279-86. PubMed ID: 19652878
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High-affinity binding sites for human Glu-plasminogen unveiled by limited plasmic degradation of human fibrin.
    Tran-Thang C; Kruithof EK; Atkinson J; Bachmann F
    Eur J Biochem; 1986 Nov; 160(3):599-604. PubMed ID: 2946579
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.